- Conditions
- Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
- Interventions
- Ibrutinib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Maywood, Illinois • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- AL Amyloidosis
- Interventions
- CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 26
- States / cities
- Duarte, California • Palo Alto, California • San Francisco, California + 20 more
- Conditions
- Gastrointestinal Cancer
- Interventions
- Cobimetinib, Hydroxychloroquine, Atezolizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Providence, Rhode Island
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1991
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more
- Conditions
- EGFR-mutated NSCLC (Disorder)
- Interventions
- MP0250 DARPin® drug candidate, Osimertinib
- Combination Product
- Lead sponsor
- Molecular Partners AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Duarte, California • San Diego, California + 7 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Everolimus, TRC105
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Systemic Infection
- Interventions
- Antibiotic
- Drug
- Lead sponsor
- Phillip Brian Smith
- Other
- Eligibility
- 14 Days to 32 Weeks
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 10
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Head and Neck Cancer, Oral Mucositis
- Interventions
- Grape extract, Lortab, Fentanyl patch, mouthwash
- Dietary Supplement · Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 20 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Uveal Melanoma
- Interventions
- LXS196, LXS196 and HDM201
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD), Placebo
- Drug · Other
- Lead sponsor
- Aravive, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Oakland, California + 12 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- ARX517, Apalutamide, Abiraterone acetate, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Rectal Cancer
- Interventions
- Chemotherapy, Celecoxib, and Radiation
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 3
- States / cities
- Albuquerque, New Mexico • Santa Fe, New Mexico
- Conditions
- HIV Infections
- Interventions
- Efavirenz, Emtricitabine, Stavudine, Didanosine
- Drug
- Lead sponsor
- Triangle Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Berkeley, California • Concord, California + 38 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more
- Conditions
- COVID-19
- Interventions
- Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN)
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Basal Cell Carcinoma
- Interventions
- Photodynamic Therapy (PDT), Metvix cream, Placebo Cream
- Radiation · Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Minneapolis, Minnesota • Rochester, Minnesota + 6 more
- Conditions
- Neuroblastoma, Neuroectodermal Tumors, Neoplasms
- Interventions
- 131I-MIBG, 131-MIBG + Vorinostat
- Drug
- Lead sponsor
- Jubilant DraxImage Inc.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 21
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 17 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
- Interventions
- Cabiralizumab, Nivolumab
- Biological
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- HIV Infections
- Interventions
- Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Chicago, Illinois • Cleveland, Ohio
- Conditions
- HIV Infections
- Interventions
- Efavirenz, Lamivudine, Stavudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 14 more
- Conditions
- HIV
- Interventions
- Truvada, Raltegravir
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Depressive Disorder
- Interventions
- Carbidopa/levodopa, Placebo, Exercise training, Control
- Drug · Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 21 more